Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio di GSK5458514 somministrato da solo o in combinazione con altri agenti anticancro nei partecipanti con carcinoma prostrato

1 ottobre 2026 aggiornato da: GlaxoSmithKline

Uno studio di fase 1/2 per la prima volta-umano, in aperto, multicentrico, escalation e espansione della dose di GSK5458514 PSMA mira a Finger T-Cell Engager o in combinazione con altri agenti anticannanici nei partecipanti agli adulti con carcinoma prostatico di castrazione metastatica (MCRPC)

The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

85

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Daniel Khalaf
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Ramy Saleh
      • Montreal, Quebec, Canada, H3T 1E2
        • Reclutamento
        • GSK Investigational Site
        • Investigatore principale:
          • April Rose
        • Contatto:
        • Contatto:
      • Lyon, Francia, 69373
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Armelle Vinceneux
      • Villejuif, Francia, 94805
        • Reclutamento
        • GSK Investigational Site
        • Investigatore principale:
          • Yohann Loriot
        • Contatto:
        • Contatto:
      • Kanagawa, Giappone, 232-0024
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Takashi Kawahara
      • Tokyo, Giappone, 104-0045
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Tatsunori Shimoi
      • Tokyo, Giappone, 135-8550
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Yuji Miura
      • Badajoz, Spagna, 06080
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Marta González Cordero
      • Barcelona, Spagna, 08023
        • Reclutamento
        • GSK Investigational Site
        • Investigatore principale:
          • Tatiana Hernandez
        • Contatto:
        • Contatto:
      • Madrid, Spagna, 28040
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Bernard Doger
      • Madrid, Spagna, 28050
        • Reclutamento
        • GSK Investigational Site
        • Investigatore principale:
          • Emiliano Calvo Aller
        • Contatto:
        • Contatto:
      • Málaga, Spagna, 29010
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Lucia Oliva Fernandez
      • Pozuelo de AlarcOn Madr, Spagna, 28223
        • Reclutamento
        • GSK Investigational Site
        • Investigatore principale:
          • VALENTINA BONI
        • Contatto:
        • Contatto:
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85054
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Investigatore principale:
          • Yousef Zakharia
        • Contatto:
    • Colorado
      • Denver, Colorado, Stati Uniti, 80218-1234
        • Reclutamento
        • GSK Investigational Site
        • Investigatore principale:
          • Gerald Falchook
        • Contatto:
        • Contatto:
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06510
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Daniel Petrylak
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55905
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Dan Childs
    • New Jersey
      • East Brunswick, New Jersey, Stati Uniti, 08816
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Bruno Fang
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Benjamin Garmezy

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

Inclusion Criteria:

  • Provide signed informed consent. Participants must be capable of providing informed consent, which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF) and in this protocol.
  • Male participants greater than equal to (>=)18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.

Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 195 days, after the last dose of study intervention:

Refrain from donating sperm

PLUS either:

Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.

OR

Must agree to use contraception as detailed below:

Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant.

  • Participants with mCRPC:

    • Histologically or cytologically confirmed adenocarcinoma of the prostate
    • Metastatic disease diagnosed either by radiologic imaging (Positron emission tomography [PET]- Computed tomography [CT]) and/or regular CT and/or Magnetic resonance imaging (MRI) and/or bone scan
    • Castration-resistant status as per PCWG3 criteria
  • Has prior novel anti-androgen receptor therapy failure and had treatment failure with 1-2 taxane-based chemotherapy regimens including for metastatic hormone sensitive prostate cancer.

  • Has (1) at least 1 soft tissue target lesion per Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) OR (2) if Non-Target soft tissue disease only per PCWG3-modified RECIST 1.1, may be included if a rise in Prostate-specific antigen (PSA) on 2 successive determinations at least 1 week apart (the most recent screening measurement must have been >= 2 nanograms per milliliter (ng/mL) with testosterone levels <50 nanograms per deciliter (ng/dL), OR (3) bone disease defined by PCWG3 (2 or more lesions on bone scan at screening), as determined by the investigator.

  • Documented disease progression on most recent systemic anti-cancer therapy defined by fulfilling at least 1 of the PCWG3 criteria

  • Have serum testosterone <50 ng/dL (<1.7 nM). Patients must have undergone bilateral orchiectomy or be on continuous androgen-deprivation therapy with a Gonadotropin-releasing hormone (GnRH) agonist or antagonist; this therapy must have been initiated at least 4 weeks prior to randomization and treatment must be continued throughout the study.

  • Eastern Cooperative Oncology Group (ECOG) performance status <=1, with no deterioration in the 2 weeks before step-up treatment period Day 1.

  • Have supplied tumor tissue from a newly obtained biopsy or archival tumor tissue for retrospective detection of Prostate-specific membrane antigen (PSMA) expression and other biomarker analysis. Tissue from a newly obtained biopsy is preferred. If a newly obtained biopsy is not feasible, archival tumor tissue preferably taken after the completion of the participant's last line of therapy prior to the first dose of study drug is acceptable.

  • Participants must have adequate organ function

Exclusion criteria:

  • Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate or any histology different from adenocarcinoma.

  • History of central nervous system (CNS) metastases or leptomeningeal disease.

  • Diagnosis of invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years, except as noted below:

    • History of an invasive malignancy for which the participant was definitively treated, and in which the participant has been disease free for at least 2 years, and which, in the opinion of the principal investigator and medical monitor, is not expected to affect the evaluation of the effects of the study intervention on the currently targeted disease under study
    • Curatively treated basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, and/or in situ breast cancer may be enrolled
  • Has ongoing adverse reaction(s) from prior therapy that have not recovered to <=Grade 1 or to the baseline status preceding prior therapy, excluding [e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy], or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.

  • Confirmed history or recurrent autoimmune disease that has required systemic treatments in the 2 years prior to screening. Participants with prior history of autoimmune disease must be discussed with the medical monitor. Replacement therapy is not considered a form of systemic therapy (e.g., thyroid hormone for autoimmune thyroiditis or insulin is not exclusionary).

  • Has evidence of interstitial lung disease, non-infectious pneumonitis, and/or a history of interstitial lung disease, non-infectious pneumonitis that required steroid.

  • Has received any anti-cancer therapy or prior systemic biologic therapy, including immunotherapy within 30 days prior to first dose of study intervention.

  • Prior PSMA radionuclide therapy within 2 months prior to GSK5458514 unless participant received <2 cycles.

  • Prior PSMA-Chimeric antigen receptor T cell therapy (CAR-T) cell therapy and PSMA (T cell engager) TCE/ Bispecific T cell engagers (BiTE) or other prostate Tumor-associated antigens (TAA) specific T cell engager (TCE).

  • Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant.

  • Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

  • History of severe neurological or psychiatric disorder, including epilepsy, dementia, or major depression deemed to interfere with study assessments.

  • Has had any major surgery (such as craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks prior to first dose of study intervention.

  • Serious infections within 4 weeks prior to the first dose, including but not limited to infectious complications, bacteremia, severe pneumonia treated with IV antibiotics for >=2 weeks; active infections with therapeutic IV antibiotics within 2 weeks prior to the first dose or oral antibiotics within 1 week prior to the first dose. Participants who are receiving or have received prophylactic antibiotics (e.g., prophylaxis against urinary infections) are allowed.

Liver safety exclusion criteria:

  • Has an Alanine aminotransferase (ALT) value >2.5x upper limit of normal (ULN) or >5x ULN if documented history of liver metastases.
  • Has a total bilirubin value >1.5x ULN.
  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
  • Has documented presence of Hepatitis B surface antigen (HBsAg), at screening or within 3 months prior to the first dose of study intervention.
  • Has a positive Hepatitis C virus (HCV) antibody test result at screening or within 3 months prior to Cycle 1 Day 1 unless the participant can meet the following criteria: NOTE: Participants with a positive HCV antibody test result due to prior resolved disease can be enrolled if a confirmatory negative HCV RNA test is obtained and the participant otherwise meets entry criteria
  • Has a positive HCV ribonucleic acid (RNA) test result at screening or within 3 months prior to the first dose of study intervention. NOTE: The HCV RNA test is optional, and participants with a negative HCV antibody test are not required to undergo HCV RNA testing as well.
  • Is unable to adhere to the protocol defined SoA, including requirements for the Follow-up Period of the study, study procedures, restrictions, and requirements as determined by the investigator.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Parte 1: escalation della dose di monoterapia GSK5458514

GSK5458514 will be administered.

Sperimentale: Parte 2: espansione della dose di monoterapia GSK5458514

GSK5458514 will be administered.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Numero di partecipanti con dose limitanti tossicità (DLT) durante il periodo di osservazione DLT
Lasso di tempo: Fino a 28 giorni
Fino a 28 giorni
Numero di partecipanti con eventi avversi (eventi avversi), seri eventi avversi (SAE), per gravità
Lasso di tempo: Fino a circa 29 mesi
Fino a circa 29 mesi
Numero di partecipanti con eventi avversi che portano a modifiche alla dose
Lasso di tempo: Fino a circa 29 mesi
Fino a circa 29 mesi

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Area sotto concentrazione da 0 a T (AUC 0-T) di GSK5458514
Lasso di tempo: Fino a circa 32 mesi
Fino a circa 32 mesi
Concentrazione massima (CMAX) di GSK5458514
Lasso di tempo: Fino a circa 32 mesi
Fino a circa 32 mesi
Tempo per raggiungere la massima concentrazione (TMAX) di GSK5458514
Lasso di tempo: Fino a circa 32 mesi
Fino a circa 32 mesi
Numero di partecipanti con anticorpi anti-farmaco (ADA) contro GSK5458514
Lasso di tempo: Fino a circa 32 mesi
Fino a circa 32 mesi
Titoli di ADA contro GSK5458514
Lasso di tempo: Fino a circa 32 mesi
Fino a circa 32 mesi
Prostate-specific Antigen Decrease From Baseline >=50% (PSA50) Response Rate
Lasso di tempo: Up to approximately 32 months

PSA50 response rate is defined as percentage of participants with a decrease of >=50% in the PSA concentration from the baseline PSA value, confirmed at least 3 weeks later.

Up to approximately 32 months
Objective Response Rate (ORR)
Lasso di tempo: Up to approximately 32 months

ORR is defined as the percentage of participants in the ORR Evaluable set who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) per prostate cancer working group 3 (PCWG3) guidelines as assessed by investigator.

Up to approximately 32 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: GSK Clinical Trials, GlaxoSmithKline

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

12 giugno 2025

Completamento primario (Stimato)

26 ottobre 2027

Completamento dello studio (Stimato)

9 agosto 2028

Date di iscrizione allo studio

Primo inviato

22 maggio 2025

Primo inviato che soddisfa i criteri di controllo qualità

22 maggio 2025

Primo Inserito (Effettivo)

25 maggio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 ottobre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Periodo di condivisione IPD

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Criteri di accesso alla condivisione IPD

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi